LipoScience Announces 2014 First Quarter Financial Results
GlobeNewswire - Mon May 12, 3:07PM CDT
LipoScience, Inc. (Nasdaq:LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced its financial results for the first quarter ended March 31, 2014.
LipoScience Announces Cash Management Actions
GlobeNewswire - Mon May 05, 5:30AM CDT
In a proactive effort to manage its cash, LipoScience, Inc. (Nasdaq:LPDX) today announced a reduction in workforce. This announcement represents the latest step in the Company's efforts to streamline its operations and further manage its operating costs. The action, taken in response to the Company's March 28, 2014 decision to terminate its contract with Health Diagnostic Laboratory, resulted in a reduction of approximately 22 positions across the Company.
Outcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in Patients at Elevated Cardiovascular Risk
PR Newswire - Fri May 02, 7:30AM CDT
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data suggesting that the use of a target low-density lipoprotein particle (LDL-P) number to guide statin therapy in at-risk patients can reduce the risk of major adverse cardiovascular events (MACE) and death, compared to using standard LDL cholesterol (LDL-C) targets as a guide to therapy. Such benefits are particularly pronounced in patients in whom LDL-P and LDL-C numbers disagree, as is common in people with diabetes mellitus or coronary heart disease (CHD).
Omnicare Q1 Earnings Beat by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:30PM CDT
Omnicare Inc. (OCR) reported an earnings beat and in-line revenues for the first quarter of 2014, with both increasing on year-over-year bases.
LipoScience to Release First Quarter 2014 Financial Results
GlobeNewswire - Mon Apr 28, 3:17PM CDT
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its first quarter 2014 financial results after the market close on Monday, May 12, 2014. An investor conference call will follow on the same day at 4:30 P.M. ET.
Patients Managed to Target LDL Particle Number Experience Fewer Cardiovascular Events Than Patients Managed to Target LDL Cholesterol, According to Study
PR Newswire - Mon Mar 31, 8:30AM CDT
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data showing that patients managed to a target LDL particle (LDL-P) number, as measured by LipoScience's NMR LipoProfile test, achieved a 22 to 25 percent greater reduction in the risk of cardiovascular (CV) events over a three-year period compared to patients who attained LDL cholesterol (LDL-C) targets.
Nasdaq stocks posting largest volume increases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why LipoScience (LPDX) Stock Hit a One-Year Low Today
at The Street - Fri Mar 28, 1:03PM CDT
LipoScience (LPDX) fell to a one-year low on Friday after the diagnostics technology company decreased its first-quarter guidance to less than analysts' estimates after it ended its contract with Health Diagnostic Laboratory. The company reduced its...
LipoScience Announces Termination of Contract With Health Diagnostics Laboratory
GlobeNewswire - Fri Mar 28, 5:45AM CDT
LipoScience, Inc. (Nasdaq:LPDX) today announced the termination of its relationship with Health Diagnostics Laboratory, Inc. ("HDL Inc."
LipoScience (LPDX) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:33AM CDT
LipoScience (LPDX) Sees Hammer Chart Pattern: Time to Buy?
LipoScience Announces 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Mar 10, 3:05PM CDT
LipoScience, Inc. (Nasdaq:LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2013.
LipoScience to Present at Barclays Global Healthcare Conference
GlobeNewswire - Thu Feb 27, 6:45AM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced that Howard Doran, President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 11:15 A.M. ET on Wednesday, March 12, 2014, in Miami, FL.
LipoScience to Release Fourth Quarter and Fiscal Year 2013 Financial Results
GlobeNewswire - Mon Feb 24, 3:05PM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Monday, March 10, 2014. An investor conference call will follow on the same day at 4:30 P.M. ET.
LipoScience names Howard Doran as president & CEO
M2 - Thu Jan 23, 7:15AM CST
US-based diagnostics NMR company LipoScience Inc (NasdaqGM:LPDX) revealed on Wednesday the election of Howard Doran as its president, CEO and as a member of the board of directors, with effect from 3 February 2014.
LipoScience Announces Appointment of Howard Doran as President and Chief Executive Officer
GlobeNewswire - Wed Jan 22, 7:00AM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced the appointment of Howard Doran to the position of President and Chief Executive Officer and as a member of the LipoScience, Inc. Board of Directors, effective February 3, 2014.
LipoScience Inc to participate at 25th Annual Piper Jaffray Healthcare Conference in New York City
M2 - Thu Nov 28, 8:02AM CST
Diagnostic test company LipoScience Inc (NasdaqGM:LPDX) stated on Wednesday that it will take part at the 25th Annual Piper Jaffray Healthcare Conference in New York City.
LipoScience to Present at 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Wed Nov 27, 5:30AM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced that Bob Greczyn, Interim President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the 25 Annual Piper Jaffray Healthcare Conference at 11:00 A.M. ET on Wednesday, December 4, 2013, in New York City.
LipoScience Announces Agreement With Scripps Health For First California Placement Of Vantera® Clinical Analyzer
PR Newswire - Mon Nov 25, 8:00AM CST
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced an agreement to place the Vantera® Clinical Analyzer within Scripps Health facilities. The agreement, which marks the first placement of the Vantera Clinical Analyzer in the state of California, will make NMR lipoprotein testing on the analyzer accessible to customers of Scripps Health.
LipoScience to Discuss 2014 Guidance on Fourth Quarter 2013 Financial Results Conference Call
GlobeNewswire - Thu Nov 21, 3:05PM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will discuss revenue guidance for 2014 on the Company's Fourth Quarter 2013 conference call rather than on December 3, 2013 as previously announced. Management believes this timing will allow for greater visibility into factors that may influence 2014 revenue, including implementation of the Affordable Care Act (ACA) and publication of the latest laboratory fee schedule by the Centers of Medicare and Medicaid Services (CMS).
Real-World Data Presented At AHA Scientific Sessions Demonstrate Relationship Between Low-Density Lipoprotein Particle (LDL-P) Number And Future Risk Of Coronary Heart Disease
PR Newswire - Mon Nov 18, 9:30AM CST
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced that low-density lipoprotein particle (LDL-P) number can predict cardiovascular events independently of LDL cholesterol (LDL-C) concentrations in a real-world environment, as presented in a poster session at the 2013 Scientific Sessions of the American Heart Association.